Regen BioPharma Three New Series of Compounds That Activate NR2F6

Regen BioPharma has identified three new series of compounds that activate NR2F6. These compounds are small molecules and were identified using Regen’s patented screening methodology and unique chemical libraries. ChemDiv, Inc. is a fully integrated Target-to-Clinic Contract Research Organization headquartered in San Diego, CA.

The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient’s own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.

Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen said that finding small molecules that activate NR2F6 is very difficult. They have been fortunate in identifying three additional classes of compounds which do this. In the drug development process, it is very important to have a backup set of small molecules to develop into clinical candidates. That way, if one class of compounds fail in the development process another small molecule with a different central structure can be substituted and the program can continue.